You may have been redirected to this web page from the UAS Labs web page as an online action following Chr. Hansen’s acquisition of UAS Labs

Man in park smiling

Lactobacillus reuteri NCIMB 30242, LRC®

Heart health strain contributes to normal vitamin D production and good cholesterol levels

The heart health strain Lactobacillus reuteri NCIMB 30242 (LRC®), hereafter referred to by use of the trademark, LRC®, is one of Chr. Hansen’s top contributions to probiotic use in new health areas.

This award-winning probiotic strain for heart health is backed by intensive probiotic scientific research.

 

Contributes to normal vitamin D production and cholesterol level maintenance

The LRC® strain has been associated with several health benefits. Some studies indicate that it may:

  • Naturally support total cholesterol levels already within the normal range1, 2
  • Support the body’s normal production of Vitamin D3
  • Support overall digestive health.4


How Chr. Hansen identified the LRC
® strain

A proprietary Chr. Hansen technology was used to narrow a selection of more than 350 strains down to one. This technology identified probiotic candidates with the potential to support better health and natural balance.

Strains were validated for bile salt hydrolase (BSH) activity, GIT viability, commercialization characteristics, and finally screened in human scientific studies.

In the end Lactobacillus reuteri  NCIMB 30242 was selected for its ability to naturally help support total and cholesterol levels already within the normal range.

 

Scientific documentation of the benefits of the LRC® strain

The LRC® strain is supported by multiple randomized, double blind, placebo-controlled human studies. A sampling of the study results can be found below:

Study in adults supporting heart health
A study completed to evaluate the support for heart health and safety of an LRC® capsule in adults with mild cholesterol issues resulted in an 11.6% reduction in cholesterol, as compared to placebo, over nine weeks.2

Study in adults supporting normal vitamin D levels
During a randomized, double-blind, placebo-controlled study, subjects receiving the LRC® strain attained a significant increase of 22.4% (as compared to placebo) in circulating 25-hydroxyvitamin D after nine weeks.3

 

Awards for LRC®

The LRC® strain won the NEXT Innovation Summit’s NutraAward 2014 for best new ingredient, presented at Natural Products Expo West.


Proven stable in several delivery formats

The LRC® strain has proven stable in a variety of delivery formats including supplements and some other foods. Its ability to withstand harsh processing means there are many application possibilities. 


 

References 
1 Jones et al. Br J Nutr 2012.
2 Jones et al. Euro J Clin Nutr 2012.
3 Jones et al. J Clin Endocrinol Metab 2013.
4 Jones et al. Exp Opin Biol Ther 2013.

 

LRC® is a registered trademark of Chr. Hansen A/S.


 

This communication is only intended for business-to-business and health care professionals. This communication is not intended for consumers of final consumer goods. Nothing on this page is meant to be perceived as an approved claim.  

Share this with: